Agents that target CXCR4, including small molecule inhibitors, monoclonal antibodies (mAbs), and peptide antagonists, have been shown to disrupt SDF-1/CXCR4 binding and downstream signaling with therapeutic applications in cancer and immunopathology. This evidence concerns the gene CXCL12 and cancer.